S&P Futures
4,170.50 -21.00 (-0.50%) Dow Futures
34,114.00 +17.00 (+0.05%) Nasdaq Futures
12,661.75 -185.00 (-1.44%) Russell 2000 Futures
2,007.40 -0.50 (-0.02%) Crude Oil
75.68 -0.20 (-0.26%) Gold
1,929.80 -1.00 (-0.05%)
Kezar Life Sciences, Inc. (KZR)
After hours:
Chart Events
Performance Outlook
| Previous Close | 6.90 |
| Open | 6.94 |
| Bid | 7.17 x 1100 |
| Ask | 8.60 x 800 |
| Day's Range | 6.93 - 7.32 |
| 52 Week Range | 4.31 - 18.55 |
| Volume | |
| Avg. Volume | 662,960 |
| Market Cap | 388.877M |
| Beta (5Y Monthly) | 0.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.95 |
| Earnings Date | Mar 15, 2023 - Mar 20, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.75 |
- Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., January 13, 2023--Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company’s Board of Directors granted two employees nonqualified stock options to purchase 65,000 shares of its common stock with an exercise price of $6.84 per share, which is equal to the closing price of Kezar’s common
- Business Wire
Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., January 04, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that John Fowler, Co-founder and Chief Executive Officer, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 2:15 pm PT in San Francisco, CA.
- Business Wire
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022
SOUTH SAN FRANCISCO, Calif., November 14, 2022--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it presented the complete data set from the MISSION Phase 2 clinical trial evaluating zetomipzomib in active lupus nephritis (LN) at the American College of Rheumatology (ACR) Convergence 2022 in Philadelphia, PA.
